Patent application number | Description | Published |
20080293817 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 11-27-2008 |
20090281188 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 11-12-2009 |
20090305209 | Online protocol/tool for evaluating acne lesions - A web-based protocol/tool to improve the identification and characterization process of evaluators in recognizing and distinguishing acne lesions, included at least the following program activities:
| 12-10-2009 |
20100029762 | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris - A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor. | 02-04-2010 |
20100069495 | Topical application of adapalene for the long-term treatment of acne vulgaris - Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two days for at least 6 months. | 03-18-2010 |
20100273882 | METHOD FOR THE TREATMENT OF ACNE USING COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID - Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions. | 10-28-2010 |
20110027204 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 02-03-2011 |
20110027367 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 02-03-2011 |
20110070176 | METHOD FOR THE TREATMENT OF ACNE USING COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID - Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions. | 03-24-2011 |
20110130461 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 06-02-2011 |
20110224216 | Methods of Treating or Preventing Acute Erythema - A method of treating or preventing acute erythema in a human in need thereof by topical administration of an effective amount of an alpha adrenergic receptor agonist or pharmaceutically acceptable salt thereof is claimed. The preferred alpha adrenergic receptor agonist is brimonidine. A method of preventing secondary inflammation caused by acute erythema by topical administration of an effective amount of an alpha adrenergic receptor agonist or a pharmaceutically acceptable salt thereof is also claimed. | 09-15-2011 |
20110286944 | METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF ERYTHEMA - Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier. | 11-24-2011 |
20110288096 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 11-24-2011 |
20120076738 | COMBINATION TREATMENT FOR DERMATOLOGICAL CONDITIONS - The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier. | 03-29-2012 |
20120082625 | COMBINATION TREATMENT FOR ROSACEA - The invention relates to a method of treating erythema and/or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema and/or telangiectasia on the skin of the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier. | 04-05-2012 |
20120214816 | METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF ERYTHEMA - Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier. | 08-23-2012 |
20120231062 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 09-13-2012 |
20130041035 | TOPICAL APPLICATION OF ADAPALENE FOR THE LONG-TERM TREATMENT OF ACNE VULGARIS - Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two days for at least 6 months. | 02-14-2013 |
20130059857 | METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF TELANGIECTASIA - Improved methods and compositions for safe and effective treatment of telangiectasia or a symptom associated with telangiectasia in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier. | 03-07-2013 |
20130071489 | METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF ERYTHEMA - Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier. | 03-21-2013 |
20130197003 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 08-01-2013 |
20130243705 | METHOD FOR PREVENTING OR TREATING SKIN TUMOR - Methods, compositions and products for preventing skin tumor formation or inhibiting development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an α2 adrenergic receptor agonist, such brimonidine. | 09-19-2013 |
20130251649 | METHOD FOR PREVENTING OR TREATING SKIN TUMOR - Methods, compositions and products for preventing skin tumor formation or inhibiting the development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an α adrenergic receptor agonist, such as brimonidine. | 09-26-2013 |
20140080836 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 03-20-2014 |
20140094469 | METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF ERYTHEMA - Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier. | 04-03-2014 |
20140094470 | COMBINATION TREATMENT FOR DERMATOLOGICAL CONDITIONS - The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier. | 04-03-2014 |
20140100232 | COMBINATION TREATMENT FOR ROSACEA - The invention relates to a method of treating erythema and/or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema and/or telangiectasia on the skin of the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier. | 04-10-2014 |
20140249232 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 09-04-2014 |
20140308223 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions. | 10-16-2014 |
20140336257 | ADMINISTRATION OF ADAPALENE AND BENZOYL PEROXIDE FOR THE LONG-TERM TREATMENT OF ACNE VULGARIS - A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor. | 11-13-2014 |
20150045440 | METHOD FOR THE TREATMENT OF ACNE USING PHARMACEUTICAL COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID - Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions. | 02-12-2015 |